InnoCare and Lilly Sign Drug Discovery Deal With Up to $3.25 Billion in Milestones

InnoCare Pharma has signed a strategic research collaboration and licensing agreement with Eli Lilly to discover and advance medicines against up to five targets addressing unmet medical needs. InnoCare will contribute its proprietary drug-discovery platform and research expertise, while Lilly will provide global pharmaceutical capabilities. The deal could deliver up to $100 million in upfront and near-term payments, approximately $3.25 billion in development and commercial milestones, and tiered single-digit royalties on annual product sales. The companies did not disclose the specific targets or compounds, and any milestone payments will depend on successful development and commercialization. The agreement expands Lilly’s partnerships with Chinese biopharmaceutical companies and could strengthen InnoCare’s pipeline and international presence.